Aarti Drugs has commenced the new R&D center at MIDC Tarapur. Earlier, on September 26, 2013 US health regulator had issued a warning letter to company's Maharashtra facilities .The investigators of the US Food and Drug Administration had identified significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and active pharmaceutical ingredients at the companies Maharashtra facilities.
Aarti Drugs (ADL) is engaged in the business of manufacturing generic bulk actives, advanced intermediates and specialty chemicals. The company is part of $265 million Aarti Group of Industries.
No comments:
Post a Comment